Favorable outcomes of patients with sickle cell disease hospitalized due to COVID‑19: A report of three cases

Tentolouris, Anastasios; Stafylidis, Christos; Siafarikas, Christos; Dimopoulou, Maria; Makrodimitri, Sotiria; Bousi, Stelios; Papalexis, Petros; Damaskos, Christos; Τράκας, Νικόλαος; Sklapani, Pagona; Spandidos, Demetrios A.; Georgakopoulou, Vasiliki

doi:10.3892/etm.2022.11268

Cited by 3 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These manifestations have been reported since the beginning of the pandemic with significant frequency, although the cause-effect correlation cannot always be clearly determined. There are points of disagreement about the biological impact of COVID-19 in individuals with sickle cell disease, but most authors seem to agree that SARS-CoV-2 can act as a trigger for vaso-occlusive crises and acute chest syndrome ( 14 , 29 , 30 , 32 , 34 , 37 , 39 , 42 , 43 , 45 , 46 , 67 , 71 , 72 , 74 , 75 , 77 , 79 , 82 , 84 , 86 , 90 , 92 , 98 , 104 , 106 , 109 , 112 , 118 ). Explanations for this are grounded in empirical data and well-established knowledge about the mechanisms by which infections trigger complications of sickle cell disease.…”

Section: Discussionmentioning

confidence: 99%

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

et al. 2023

View full text Add to dashboard Cite

Sickle cell disease is the most common hemoglobinopathy among humans. As the condition promotes susceptibility to infections, chronic inflammation, and hypercoagulability disorders, several international agencies have included individuals with this disease in the COVID-19 risk group for severe outcomes. However, available information about the subject is not properly systematized yet. This review aimed to understand and summarize the scientific knowledge about the impact of SARS-CoV-2 infection in patients with sickle cell disease. Searches were performed in the Medline, PubMed, and Virtual Health Library databases based on descriptors chosen according to the Medical Subject Headings. We analyzed studies published between 2020 and October 2022, developed with qualitative, quantitative, or mixed methodology, and written in English, Spanish, or Portuguese. The search resulted in 90 articles organized into six categories. There is disagreement in the literature about how different aspects related to sickle cell disease, such as chronic inflammation status, hypercoagulability, hemolytic anemia, use of hydroxyurea, and access to medical care interference with the clinical course of COVID-19. These topics deserve further investigation. It is evident, however, that the infection may manifest in an atypical way and act as a trigger for the development of sickle cell-specific complications, such as acute chest syndrome and vaso-occlusive crises, conditions that are associated with great morbidity and mortality. Therefore, healthcare professionals must be aware of the different forms of presentation of COVID-19 among these individuals. Specific guidelines and therapeutic protocols, as well as public policies for sickle cell individuals, must be considered.Systematic review registrationThis review (https://doi.org/10.17605/OSF.IO/NH4AS) and the review protocol (https://osf.io/3y649/) are registered in the Open Science Framework platform.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, there is conflicting empirical evidence on whether patients with SCD experience more severe COVID-19 disease, and whether their mortality rate is greater than the general population. Some published case series and observational cohort studies reported a relatively mild and uncomplicated course [ [17] , [18] , [19] , [20] ] while others reported an increased risk of complications, hospitalization and/or death [ [21] , [22] , [23] , [24] , [25] , [26] ]. A systematic review of case reports and observational cohort studies of patients with SCD and COVID-19 described that adults typically had a mild to moderate course, with few respiratory symptoms, similar to patients without SCD; studies that described more severe disease in patients with SCD and COVID-19 reported prolonged hospitalization with hypoxia, pneumonia, prolonged fever, multisystem inflammation, as well as complications typical in SCD, such as acute chest syndrome and severe pain crisis [ [26] , [27] , [28] , [29] ].…”

Section: Overview Of Covid-19 Risk and Vaccination Benefits In Common...mentioning

confidence: 99%

Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders

Saade

Hojat²,

Gundelly³

et al. 2022

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

“…Patients with SCD at times require blood transfusions, and this may interfere with their cardiovascular health if they are also infected with COVID-19. Blood coagulation and endothelial damage are observed in patients infected with COVID 19; therefore, patients with SCD may have a higher risk as they already exhibit a poor immune system, and their blood cells are prone to sickling as well as related cardiovascular problems (20).…”

Section: Introductionmentioning

confidence: 99%

Potential inflammatory targets in the integrative health care of patients with sickle cell disease

Khan,

Halawani,

Zughaibi

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Inflammation plays an integral role in the complications of sickle cell disease (SCD), which can lead to vaso-occlusive crisis and extreme pain. SCD is accompanied by numerous complications, including cardiovascular disease, cognitive decline and endothelial dysfunction, contributing to mortality. As disease severity increases with age, the present study aimed to assess if age is also correlated with a definite pattern of progression of the two inflammatory markers, high-sensitivity C-reactive protein (hsCRP) and total homocysteine (tHCY). The findings of the present study could lead to an improved understanding of the threshold levels of these inflammatory markers and timely interventions to delay complications. In an observational study, levels of hsCRP and tHCY were analyzed in 70 patients (35 male and 35 female patients) with SCD aged between 5 and 16 years. hsCRP levels were in the high-risk range in 64.29% (n=45) of all male and female patients. A sex-wise distribution showed that, of the 35 male patients, 74.28% (n=26) were in the high-risk range, and of the 35 female patients, 54.28% (n=19) were in the high-risk range. An age-wise distribution showed that of the 41 patients in the 5-10-years age group, 70.73% (n=29), were in the high-risk range. In comparison, of the 29 patients in the 11-16-years age group, 55.17% (n=16) were in the high-risk range. tHCY levels were observed to be in the normal range in 98.57% (n=69) of all children, as compared with 1.43% (n=1) in the high-risk range. Furthermore, a sex-wise distribution showed that female patients in the high-risk group of hsCRP had higher concentrations of tHCY as compared with the male patients in that risk group. An age-wise distribution of hsCRP concentration also showed that the risk of CVD in patients in the 11-16-years age group was higher with increased concentrations of tHCY. A weak negative correlation was observed between age and hsCRP concentrations (r-value=-0.280; P=0.026) and a weak positive correlation was detected between tHCY and age (r-value= 0.259; P= 0.036). In conclusion, the results of the present study indicated that higher levels of hsCRP could be a useful marker in children with SCD, and levels of tHCY may be an adjunct marker as the disease progresses with age.

show abstract

Favorable outcomes of patients with sickle cell disease hospitalized due to COVID‑19: A report of three cases

Cited by 3 publications

References 27 publications

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders

Potential inflammatory targets in the integrative health care of patients with sickle cell disease

Contact Info

Product

Resources

About